/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines. Based in Foster City, California, the company is renowned for its focus on treating serious diseases, particularly in the areas of HIV/AIDS, liver diseases, oncology, and inflammatory conditions.
Shares of GILD have outperformed the broader market over the past year. The stock has gained 23.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 22.7%. In 2025, GILD is up 5.2% compared to SPX’s 2.7% rise on a YTD basis.